Herpes Simplex Virus (HSV) Types 1 and 2-Specific Antibodies, IgG

Use: This test is used to detect IgG antibodies specific to HSV types 1 and/or 2 infection and confirm or rule out possible infection with herpes simplex types 1 and/or 2 virus in prenatal patients in whom HSV 2 infection can cause serious prenatal disease. In a patient with no history of lesion disease, a positive result for this test may be indicative that the primary infection was asymptomatic. Once infected by HSV, it is possible for a patient to shed the virus without the development of lesions (asymptomatic shedding). This test does not indicate the site of HSV infection. The magnitude of the Index Value is not indicative of the amount of antibody present in the patient sample. There is a considerable homology between HSV-1 and HSV-2 antigens, so that antibodies formed against either virus are highly cross-reactive. These assays are based on purified recombinant glycoprotein G-1 (HSV-1) or G-2 (HSV-2) antigens.

Limitations: Serum samples collected too early in the course of infection may not have detectable levels of HSV IgG. In cases of suspected early disease, a repeat serum specimen should be collected 14-21 days later and submitted for testing. The predictive value of positive or negative results depends on the prevalence of disease and the pretest likelihood of HSV-1 and HSV-2.

False-positive results may occur. Repeat testing, or testing by a different method, may be indicated in some settings (e.g., patients with low likelihood of HSV infection).

This test is intended for qualitative determination only. The magnitude of the Index Value is not indicative of the amount of antibody present in the patient sample.

Methodology: Chemiluminescent immunoassay (CLIA)